aTYR PHARMA vs VivoSim Labs
ATYR and VIVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATYR and VIVS compare
aTYR PHARMA is the larger company, worth 1276 times as much as VivoSim Labs ($489M against $384K).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATYR | VIVS |
|---|---|---|
| Size and price | ||
| Market cap | $489M | $384K |
| Share price | $4.99 | $0.120 |
| Change, 1 year | 563% | −94.5% |
| Change, 5 years | −98.5% | −99.8% |
| Beta (5Y) | – | 2.58 |
| Employees | 58 | 15 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 3.4× |
| P/B | 10.0× | – |
| FCF yield | −11.2% (better) | −2639% |
| Growth | ||
| Revenue growth (TTM) | – | −21.1% |
| Revenue growth, 5Y average | −55.1% | – |
| Profitability | ||
| Operating margin | – | −10117% |
| Net margin | – | −11016% |
| FCF margin | – | −9038% |
| Return on equity | −98.4% (better) | −343% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −944.3× |
| Current ratio | 5.12 (better) | 1.70 |
| Altman Z-score | −0.96 (better) | −139.28 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −781% |
| Shareholder yield | 0.00% (better) | −781% |
| Ownership | ||
| Held by institutions | 41.4% | 3.2% |
| Held by insiders | 2.6% | – |
| Insider net buying, 12 months | $43.7K (better) | $2.8K |
| Short interest, % of float | 0.31% | – |
Go deeper
- ATYR stock overview
- ATYR income statement
- ATYR valuation and score
- VIVS stock overview
- VIVS income statement
- VIVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.